NCT01892345 2019-06-26A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)Alexion Pharmaceuticals, Inc.Phase 3 Terminated143 enrolled 18 charts